Transverse myelitis is a rare neurological condition that affects the spinal cord, leading to varying degrees of motor, sensory, and autonomic dysfunction. The disease affects approximately 1.76 per 1,000,000 children aged 19 years and younger globally. Currently, there is a significant unmet clinical need for effective treatments, as existing therapies primarily focus on managing symptoms, such as corticosteroids. However, the growing emphasis on immunomodulatory treatments, stem cell therapies, and targeted molecular therapies is expected to drive the development of novel treatments, offering hope for improved outcomes in the future.
The Transverse Myelitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into transverse myelitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for transverse myelitis. The transverse myelitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The transverse myelitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with transverse myelitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to transverse myelitis.
Transverse myelitis is a rare neurological condition characterized by inflammation of the spinal cord, which can lead to motor, sensory, and autonomic dysfunction. It occurs when the immune system mistakenly attacks the spinal cord, often following infections, autoimmune disorders, or after vaccination. Symptoms include weakness, pain, and sensory issues, with varying severity depending on the affected spinal region.
Transverse myelitis treatment typically involves corticosteroids to reduce inflammation. In some cases, plasma exchange therapy is used to remove harmful antibodies. Additionally, immunosuppressive drugs may help manage underlying conditions, while physical therapy assists in recovery and rehabilitation, aiming to improve mobility and function.
Studies reveal that the incidence of transverse myelitis in children under 19 years is approximately 1.76 per 1,000,000, with a peak onset of around 9.5 years. In the United States, 1 to 8 new cases are reported per million people annually. Global prevalence ranges from 0.4 to 1.5 per thousand deliveries, with a varying gender distribution, especially in older children.
This section of the report covers the analysis of transverse myelitis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total transverse myelitis clinical trials.
The drug molecule categories covered under the transverse myelitis pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for transverse myelitis.
The EMR report for the transverse myelitis report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in transverse myelitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for transverse myelitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of transverse myelitis drug candidates.
A Phase 1/2a study sponsored by Q Therapeutics, Inc. is evaluating the safety of transplanting human glial restricted progenitor cells (Q-Cells®) into subjects with transverse myelitis (TM). The study aims to assess the safety, tolerability, and early activity of Q-Cells® transplantation in spinal cord lesions.
This drug, sponsored by Hansoh BioMedical R&D company, is currently in a Phase 4 study. The objective of this study is to assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders (NMOSD), a condition that includes symptoms like transverse myelitis. The study is expected to be completed by June 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Transverse Myelitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for transverse myelitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within transverse myelitis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share